-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Genmab, Raises Price Target to $45

Benzinga·10/07/2026 16:47:13
Diffusion vocale
Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $45.